Lateral internal sphincterotomy (LIS) is a minimally invasive procedure used to treat chronic anal fissures. It involves cutting the internal sphincter muscle, which is located between the rectum and the anus. This procedure is used to reduce spasm and pain, as well as to promote healing of the fissure. While it is an effective treatment option, it is not without risks. This article will explore the benefits and risks of LIS in order to help doctors better understand this procedure and its potential impact on their patients.
Lateral internal sphincterotomy (LIS) is a surgical procedure used to treat chronic anal fissures. It involves cutting the internal sphincter muscle, which is located between the rectum and the anus. This procedure is used to reduce spasm and pain, as well as to promote healing of the fissure. The procedure is typically performed under general anesthesia. During the procedure, the surgeon makes a small incision in the sphincter muscle and then divides it in two. This reduces the tension in the muscle, which helps to reduce spasm and pain, as well as to promote healing of the fissure. The procedure is typically performed as an outpatient procedure and takes about 30 minutes to complete. After the procedure, patients typically experience some pain, bleeding, and swelling for a few days.
Lateral internal sphincterotomy is an effective treatment option for chronic anal fissures. The procedure helps to reduce spasm and pain, as well as to promote healing of the fissure. It is also a minimally invasive procedure, which means that it has a shorter recovery time and fewer risks than more invasive surgical procedures. The procedure is also relatively safe. The risks associated with the procedure are typically minor and include pain, bleeding, infection, and swelling. The procedure is also relatively cost-effective, as it is typically performed as an outpatient procedure.
Although the procedure is relatively safe, there are some risks associated with LIS. These risks include pain, bleeding, infection, and swelling. In rare cases, the procedure can also cause damage to the nerves or muscles in the area, which can lead to incontinence or other complications. Additionally, the procedure can cause scarring, which can lead to narrowing of the anal canal.
Lateral internal sphincterotomy is a minimally invasive procedure used to treat chronic anal fissures. The procedure is effective in reducing spasm and pain, as well as promoting healing of the fissure. It is also relatively safe and cost-effective. However, there are some risks associated with the procedure, including pain, bleeding, infection, swelling, nerve or muscle damage, and scarring. Doctors should weigh the risks and benefits of LIS when considering this procedure for their patients.
1.
Imfinzi + Imjudo, EU approved for patients with advanced lung cancer and non-small cell lung cancer: AstraZeneca
2.
More Support for Early Detection; Cancer in Men Rising; Diet Drives Colon Cancer
3.
Asymptomatic Brain Metastases in EGFR-Mutant NSCLC
4.
Mapping lifelong chronic health risks for childhood cancer survivors
5.
Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC
1.
Respiratory Ramifications of Systemic Disease: A Comprehensive Review
2.
Revolutionizing Lung Cancer Treatment: Exploring the Benefits of Wedge Resection Surgery
3.
Trends in Incidence, Care, and Surgery for Medullary Thyroid Cancer: A Review
4.
Cancer Care Advances: Metformin, Digital Tools, and Artificial Renal Support
5.
Molecular Mechanisms, Clinical Efficacy, and Stem Cell Therapy Integration in Leukemia Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions
2.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
3.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation